Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 4/2009

01-12-2009 | Original paper

NDRG1 and CRK-I/II are regulators of endothelial cell migration under intermittent hypoxia

Authors: Sébastien Toffoli, Edouard Delaive, Marc Dieu, Olivier Feron, Martine Raes, Carine Michiels

Published in: Angiogenesis | Issue 4/2009

Login to get access

Abstract

Intermittent Hypoxia (IH) that develops in neovascularized solid tumours has been described to positively influence the tumour growth by modulating the behaviour of cancer cells as well as of endothelial cells. However, the molecular mechanisms regulated by IH still remain poorly understood. In this work, the effects of IH were investigated on endothelial cells by a proteomic approach. Protein abundance variations were studied using fluorescent 2D-Differential in Gel Electrophoresis (2D-DIGE). Amongst the proteins of which the abundance varied under IH, NDRG1 and CRK-I/II were identified by mass spectrometry. These proteins have already been described to influence cancer cell migration as well as the angiogenic processes in solid tumours. Since an increase in endothelial cell migration under IH was evidenced in our previous work, the involvement of NDRG1 and CRK-I/II proteins in endothelial cell migration under IH was determined by silencing the expression of both proteins using siRNA. The results revealed that NDRG1 and CRK-I/II are indeed regulators of endothelial cell migration under intermittent hypoxia: silencing of CRK-I/II resulted in an increase in endothelial cell migration, whereas the invalidation of NDRG1 decreased it. These results give news insight regarding the effects of IH on endothelial cell migration and hence on neoangiogenesis.
Literature
1.
Toffoli S, Michiels C (2008) Intermittent hypoxia is a key regulator of cancer cell, endothelial cell interplay in tumours. Febs J 275:2991–3002CrossRefPubMed
2.
Dewhirst MW (2007) Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res 67:854–855CrossRefPubMed
3.
Yamaura H, Matsuzawa T (1979) Tumor regrowth after irradiation; an experimental approach. Int J Radiat Biol Relat Stud Phys Chem Med 35:201–219CrossRefPubMed
4.
Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, Michiels C, Dessy C, Feron O (2006) Preconditioning of the tumor vasculature, tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66:11736–11744CrossRefPubMed
5.
Cairns RA, Kalliomaki T, Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61:8903–8908PubMed
6.
Toffoli S, Roegiers A, Feron O, Van Steenbrugge M, Ninane N, Raes M, Michiels C (2009) Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis 12:47–67
7.
Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR (2008) Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol 164:277–281CrossRefPubMed
8.
Freeman WM, Hemby SE (2004) Proteomics for protein expression profiling in neuroscience. Neurochem Res 29:1065–1081CrossRefPubMed
9.
Edgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80:3734–3737CrossRefPubMed
10.
Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Gregoire V, Gallez B, Dessy C, Feron O (2009) Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells–new insights for anti-tumor treatments. Febs J 276:509–518CrossRefPubMed
11.
Endo A, Fukuhara S, Masuda M, Ohmori T, Mochizuki N (2003) Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal Transduct Res 23:239–254CrossRefPubMed
12.
Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S (2005) Direct recruitment of CRK, GRB2 to VEGFR-3 induces proliferation, migration, survival of endothelial cells through the activation of ERK, AKT, JNK pathways. Blood 106:3423–3431CrossRefPubMed
13.
Stoletov KV, Gong C, Terman BI (2004) Nck and Crk mediate distinct VEGF-induced signaling pathways that serve overlapping functions in focal adhesion turnover, integrin activation. Exp Cell Res 295:258–268CrossRefPubMed
14.
Hopfl G, Ogunshola O, Gassmann M (2004) HIFs tumors-causes, consequences. Am J Physiol Regul Integr Comp Physiol 286:R608–R623PubMed
15.
Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229CrossRefPubMed
16.
Brahimi-Horn MC, Pouyssegur J (2007) Hypoxia in cancer cell metabolism, pH regulation. Essays Biochem 43:165–178CrossRefPubMed
17.
Toffoli S, Feron O, Raes M, Michiels C (2007) Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta 1773:1558–1571CrossRefPubMed
18.
Zeleznikar RJ, Heyman RA, Graeff RM, Walseth TF, Dawis SM, Butz EA, Goldberg ND (1990) Evidence for compartmentalized adenylate kinase catalysis serving a high energy phosphoryl transfer function in rat skeletal muscle. J Biol Chem 265:300–311PubMed
19.
Miclet E, Stoven V, Michels PA, Opperdoes FR, Lallemand JY, Duffieux F (2001) NMR spectroscopic analysis of the first two steps of the pentose-phosphate pathway elucidates the role of 6-phosphogluconolactonase. J Biol Chem 276:34840–34846CrossRefPubMed
20.
Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13:1442–1453CrossRefPubMed
21.
Ellen TP, Ke Q, Zhang P, Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29:2–8CrossRefPubMed
22.
Cangul H (2004) Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 5:27CrossRefPubMed
23.
Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M (2002) Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110(Suppl 5):783–788PubMed
24.
Akiba J, Ogasawara S, Kawahara A, Nishida N, Sanada S, Moriya F, Kuwano M, Nakashima O, Yano H (2008) N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncol Rep 20:1329–1335PubMed
25.
Chua MS, Sun H, Cheung ST, Mason V, Higgins J, Ross DT, Fan ST, So S (2007) Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20:76–83CrossRefPubMed
26.
Wang Z, Wang F, Wang WQ, Gao Q, Wei WL, Yang Y, Wang GY (2004) Correlation of N-myc downstream-regulated gene 1 overexpression with progressive growth of colorectal neoplasm. World J Gastroenterol 10:550–554PubMed
27.
Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, Gonen M, Schwartz GK (2005) Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res 11:3296–3302CrossRefPubMed
28.
Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, Aoyagi S, Kinoshita H, Kuwano M (2006) Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 66:6233–6242CrossRefPubMed
29.
Agarwala KL, Kokame K, Kato H, Miyata T (2000) Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein. Biochem Biophys Res Commun 272:641–647CrossRefPubMed
30.
Sugiki T, Murakami M, Taketomi Y, Kikuchi-Yanoshita R, Kudo I (2004) N-myc downregulated gene 1 is a phosphorylated protein in mast cells. Biol Pharm Bull 27:624–627CrossRefPubMed
31.
Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, Maercker C, Zeier M, Huber PE, Abdollahi A (2008) Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 7:1656–1668CrossRefPubMed
32.
Tu LC, Yan X, Hood L, Lin B (2007) Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 6:575–588CrossRefPubMed
33.
Lamorte L, Rodrigues S, Naujokas M, Park M (2002) Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. J Biol Chem 277:37904–37911CrossRefPubMed
34.
Rodrigues SP, Fathers KE, Chan G, Zuo D, Halwani F, Meterissian S, Park M (2005) CrkI and CrkII function as key signalling integrators for migration and invasion of cancer cells. Mol Cancer Res 3:183–194PubMed
35.
Feller SM (2001) Crk family adaptors-signalling complex formation and biological roles. Oncogene 20:6348–6371CrossRefPubMed
36.
Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M (1992) Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol 12:3482–3489PubMed
37.
Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA (1998) CAS/Crk coupling serves as a “molecular switch” for induction of cell migration. J Cell Biol 140:961–972CrossRefPubMed
38.
Uemura N, Griffin JD (1999) The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem 274:37525–37532CrossRefPubMed
39.
Tsuda M, Makino Y, Iwahara T, Nishihara H, Sawa H, Nagashima K, Hanafusa H, Tanaka S (2004) Crk associates with ERM proteins and promotes cell motility toward hyaluronic acid. J Biol Chem 279:46843–46850CrossRefPubMed
40.
Yano H, Uchida H, Iwasaki T, Mukai M, Akedo H, Nakamura K, Hashimoto S, Sabe H (2000) Paxillin alpha and Crk-associated substrate exert opposing effects on cell migration and contact inhibition of growth through tyrosine phosphorylation. Proc Natl Acad Sci USA 97:9076–9081CrossRefPubMed
Metadata
Title
NDRG1 and CRK-I/II are regulators of endothelial cell migration under intermittent hypoxia
Authors
Sébastien Toffoli
Edouard Delaive
Marc Dieu
Olivier Feron
Martine Raes
Carine Michiels
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 4/2009
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-009-9156-2

Other articles of this Issue 4/2009

Angiogenesis 4/2009 Go to the issue

Brief Communication

Capillary arterialization requires the bone marrow-derived cell (BMC)-specific expression of chemokine (C-C motif) receptor-2, but BMCs do not transdifferentiate into microvascular smooth muscle

Original Paper

Influence of the oxygen microenvironment on the proangiogenic potential of human endothelial colony forming cells

Original paper

Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor

Original Paper

Pigment epithelium–derived factor down regulates hyperglycemia-induced apoptosis via PI3K/Akt activation in goat retinal pericytes

OriginalPaper

Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis

Original Paper

RETRACTED ARTICLE: PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits